Vaped Phenanthrene

NCT ID: NCT07134426

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-01

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.

This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Former Smoker Non-Smoker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D10-phenanthrene

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Group Type OTHER

D10-phenanthrene

Intervention Type OTHER

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D10-phenanthrene

All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 21 years of age
* In good physical \& mental health
* In stable physical \& mental health
* Have tried vaping
* Former daily cigarette smokers who quit 1-20 year ago
* Non-smokers who have not used tobacco or nicotine products

Exclusion Criteria

* Has any respiratory disease (ex - asthma, COPD, etc...)
* Has/had high blood pressure
* Has/had liver disease
* Has/had cancer
* Has experience negative effects when vaped previously
* Pregnant or nursing
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Minnesota

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen Hecht

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nya Jock

Role: CONTACT

612-624-4568

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nya Jock

Role: primary

612-624-4568

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022LS127

Identifier Type: -

Identifier Source: org_study_id